Ionis Pharmaceuticals Competitors and Similar CompaniesClear all

Ionis Pharmaceuticals's competitors and similar companies include Lannett, Intellia Therapeutics, Ultragenyx, Bluebird Bio, Sarepta Therapeutics, Reata Pharmaceuticals, Arrowhead Pharmaceuticals and Alnylam.

	Ionis Pharmaceuticals Ionis Pharmaceuticals (formerly known as Isis Pharmaceuticals) is a company that discovers and develops RNA-targeted therapeutics.	Lannett Lannett is a company that specializes in pharmaceutical product families.	Intellia Therapeutics Intellia Therapeutics is a genome editing company that caters to the biotechnology industry.	Ultragenyx Ultragenyx Pharmaceutical is a company that develops therapies for rare genetic diseases.	Bluebird Bio Bluebird Bio is a developer of gene therapies for severe genetic diseases.	Sarepta Therapeutics Sarepta Therapeutics is a biopharmaceutical company specializing in the discovery and development of RNA-targeted therapeutics, gene therapy and, other genetic therapeutic modalities for the treatment of rare diseases.	Reata Pharmaceuticals Reata Pharmaceuticals is a biopharmaceutical company that develops therapeutics for patients with serious or life-threatening diseases.	Arrowhead Pharmaceuticals Arrowhead Pharmaceuticals is a biopharmaceutical company that specializes in drug development.	Alnylam Alnylam is a biopharmaceutical company that develops ribonucleic acid interference (RNAi) therapeutics for hepatic porphyria, primary hyperoxaluria type 1 (PH1), cardiovascular, and polyneuropathy treatments.
Founding Date	Founding Date 1989	Founding Date 1942	Founding Date 2014	Founding Date 2010	Founding Date 1992	Founding Date 1980	Founding Date 2002	Founding Date 2001	Founding Date 2002
Type	Type Public	Type Public	Type Public	Type Public	Type Public	Type Public	Type Public	Type Public	Type Public
Tags	Tags Healthcare biotech drug development genetics pharma	Tags Healthcare biotech drug development pharma	Tags Healthcare biotech clinical research healthtech	Tags Healthcare biotech drug development genetics pharma therapy	Tags Healthcare biotech drug development genetics	Tags Healthcare biotech drug development genetics	Tags Healthcare biotech drug development pharma	Tags Healthcare biotech drug development therapy	Tags Healthcare biotech pharma
Locations	Locations Carlsbad, US HQ	Locations Trevose, US HQ Philadelphia, US	Locations Cambridge, US HQ	Locations Novato, US HQ Buenos Aires, AR São Paulo, BR Bogotá, CO Paris, FR Berlin, DE Tokyo, JP see more	Locations Somerville, US HQ	Locations Cambridge, US HQ Dublin, IE Zug, CH Providence, US	Locations Plano, US HQ Irving, US Plano, US	Locations Pasadena, US HQ Madison, US San Diego, US	Locations Cambridge, US HQ Paris, FR Milan, IT Tokyo, JP Amsterdam, NL Stockholm, SE Zug, CH see more
Employees	Employees 92716% increase	Employees 56031% decrease	Employees 40323% decrease	Employees 1,2763% decrease	Employees 32338% decrease	Employees 1,31413% increase	Employees 3217% decrease	Employees 13416% increase	Employees 1,32324% increase
Valuation ($)	Valuation ($) 6.3 b	Valuation ($) 7.4 m	Valuation ($) 1.7 b	Valuation ($) 4.9 b	Valuation ($) 95.4 m	Valuation ($) 12.4 b	Valuation ($) 6.6 b	Valuation ($) 2.5 b	Valuation ($) 36.5 b
Financial
Revenue (est.)	Revenue (est.) $705.1m (FY, 2024)	Revenue (est.) $340.6m (FY, 2022)	Revenue (est.) $57.9m (FY, 2024)	Revenue (est.) $560.2m (FY, 2024)	Revenue (est.) $83.8m (FY, 2024)	Revenue (est.) $1.9b (FY, 2024)	Revenue (est.) $2.2m (FY, 2022)	Revenue (est.) $3.6m (FY, 2024)	Revenue (est.) $2.2b (FY, 2024)
Cost of goods	Cost of goods $11.2m (FY, 2024)	Cost of goods $294.5m (FY, 2022)	Cost of goods N/A	Cost of goods N/A	Cost of goods $89.4m (FY, 2024)	Cost of goods N/A	Cost of goods N/A	Cost of goods N/A	Cost of goods $306.5m (FY, 2024)
Gross profit	Gross profit $693.9m (FY, 2024)	Gross profit $33.2m (FY, 2022)	Gross profit N/A	Gross profit N/A	Gross profit ($5.6m) (FY, 2024)	Gross profit N/A	Gross profit N/A	Gross profit N/A	Gross profit $1.9b (FY, 2024)
Net income	Net income ($453.9m) (FY, 2024)	Net income ($231.6m) (FY, 2022)	Net income ($519m) (FY, 2024)	Net income ($569.2m) (FY, 2024)	Net income ($240.7m) (FY, 2024)	Net income $235.2m (FY, 2024)	Net income ($311.9m) (FY, 2022)	Net income ($609.7m) (FY, 2024)	Net income ($278.2m) (FY, 2024)
Operating ⚠
Patents Issued	Patents Issued N/A	Patents Issued N/A	Patents Issued N/A	Patents Issued N/A	Patents Issued N/A	Patents Issued N/A	Patents Issued 240 (FY, 2016)	Patents Issued 359 (FY, 2016)	Patents Issued N/A
Phase I Trials Products	Phase I Trials Products 1 (FY, 2023)	Phase I Trials Products N/A	Phase I Trials Products N/A	Phase I Trials Products N/A	Phase I Trials Products N/A	Phase I Trials Products N/A	Phase I Trials Products 2 (FY, 2016)	Phase I Trials Products N/A	Phase I Trials Products N/A
Phase II Trials Products	Phase II Trials Products 13 (FY, 2023)	Phase II Trials Products N/A	Phase II Trials Products N/A	Phase II Trials Products N/A	Phase II Trials Products N/A	Phase II Trials Products N/A	Phase II Trials Products 4 (FY, 2016)	Phase II Trials Products N/A	Phase II Trials Products N/A
Phase III Trials Products	Phase III Trials Products 9 (FY, 2023)	Phase III Trials Products N/A	Phase III Trials Products N/A	Phase III Trials Products N/A	Phase III Trials Products N/A	Phase III Trials Products N/A	Phase III Trials Products 1 (FY, 2016)	Phase III Trials Products N/A	Phase III Trials Products N/A
Funding
Total funding raised	Total funding raised N/A	Total funding raised N/A	Total funding raised N/A	Total funding raised $ 200.1m	Total funding raised $ 409m	Total funding raised N/A	Total funding raised $ 468.9m	Total funding raised $ 147.1m	Total funding raised $ 1.5b